Robin L Smith
CIK 1365035 · Executive Chair of the Board · last filed 2025-05-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.4K
Companies
11
Total Filings
95
Lifetime Open-Market Net
$54.69M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MTNB | Director | — | $0.29 | — | $0 | 1 | 2025-05-02 |
| CELUW | Director | 236,066 | $0.00 | $449 | $0 | 5 | 2023-06-16 |
| Sorrento Therapeutics, Inc. (SRNE) Delisted | Director | 135,000 | $0.00 | $68 | $90.9K | 5 | 2021-09-03 |
| CONCENTRIX SERVICESOURCE INC. (SREV) Delisted | Director | 167,975 | $1.50 | $252.0K | $85.0K | 3 | 2020-05-21 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | — | $0.39 | — | $0 | 2 | 2020-01-07 |
| RMTI | Director | 285 | $6.99 | $2.0K | $0 | 4 | 2019-06-10 |
| Emmaus Life Sciences, Inc. (MYNDW) Delisted | Director | 211,539 | — | — | $0 | 9 | 2019-05-10 |
| Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Director | 1,900 | — | — | $0 | 5 | 2017-02-07 |
| LISATA THERAPEUTICS, INC. (NBS) Delisted | Executive Chair of the Board | 347,285 | — | — | $24.8K | 11 | 2015-06-04 |
| LISATA THERAPEUTICS, INC. (NBS.WS) Delisted | Chairman of the Board and CEO | 1,659,533 | — | — | $37.7K | 32 | 2012-07-06 |
| LISATA THERAPEUTICS, INC. (NBS.U) Delisted | CEO and Chairman of the Board | 130,562 | — | — | $54.45M | 2 | 2007-10-01 |
Recent Filings · Page 2 of 10
95 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-14 | CONCENTRIX SERVICESOURCE INC. (SREV) Delisted | Grant (A) | +100,000 | $0 | EDGAR |
| 2020-03-06 | CONCENTRIX SERVICESOURCE INC. (SREV) Delisted | Grant (A) | +17,975 | $0 | EDGAR |
| 2020-03-05 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Buy (P) | +40,000 | $90.9K | EDGAR |
| 2020-01-07 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-12-18 | Sorrento Therapeutics, Inc. (SRNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-10 | RMTI | Grant (A) | +21,566 | $0 | EDGAR |
| 2019-05-10 | Emmaus Life Sciences, Inc. (MYNDW) Delisted | Grant (A) | +50,000 | $59.5K | EDGAR |
| 2019-03-21 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-10 | Emmaus Life Sciences, Inc. (MYNDW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-09-25 | Emmaus Life Sciences, Inc. (MYNDW) Delisted | Grant (A) | +13,513 | $25.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.